HMGN (Hemagen Diagnostics) Selling, General, & Admin. Expense: $2.01 Mil (TTM As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Selling, General, & Admin. Expense?

Hemagen Diagnostics HMGN Selling, General, & Admin. Expense is $2.01 Mil as of Sep. 2012.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Hemagen Diagnostics's selling, general, & admin. expense for the three months ended in Sep. 2012 was $0.43 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2012 was $2.01 Mil.


Hemagen Diagnostics  (OTCPK:HMGN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Hemagen Diagnostics Selling, General, & Admin. Expense Related Terms


Hemagen Diagnostics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Selling, General, & Admin. Expense Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.51 2.33 2.10 2.43 2.01

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.66 0.45 0.47 0.43

HMGN vs OBMP, NSPX, ATRX: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Hemagen Diagnostics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Selling, General, & Admin. Expense falls into.



Hemagen Diagnostics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $2.01 Mil mean?
Hemagen Diagnostics (HMGN) has a Selling, General, & Admin. Expense of $2.01 Mil as of Sep. 2012. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Selling, General, & Admin. Expense too high?
Hemagen Diagnostics' current Selling, General, & Admin. Expense is $2.01 Mil.
How does Hemagen Diagnostics' Selling, General, & Admin. Expense compare to OBMP and NSPX?
Hemagen Diagnostics' Selling, General, & Admin. Expense of $2.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current Selling, General, & Admin. Expense is $2.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Selling, General, & Admin. Expense of $2.01 Mil. The current Selling, General, & Admin. Expense is $2.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Selling, General, & Admin. Expense is $2.01 Mil as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.